Literature DB >> 9045669

Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB.

D T Loo1, N J Chalupny, J Bajorath, W W Shuford, R S Mittler, A Aruffo.   

Abstract

The T cell activation antigen 4-1BB (CDw137) is a distantly related member of the tumor necrosis factor receptor family of cell surface receptors. We previously reported that murine 4-1BB (m4-1BB) bound to extracellular matrix (ECM) proteins. Recently, a tumor necrosis factor-like ligand of m4-1BB, m4-1BBL, as well as the human counterparts of 4-1BB (ILA) and 4-1BBL (h4-1BB and h4-1BBL, respectively) have been cloned. No information is currently available on how binding of m4-1BB to ECM proteins affects its binding to m4-1BBL and vice versa and if the ability of m4-1BB to bind ECM proteins is conserved across species. We report that binding of m4-1BBL to m4-1BB blocked its ability to bind laminin (LN), while binding of m4-1BB to LN did not block its ability to bind m4-1BBL. Furthermore, binding of m4-1BBL to the m4-1BB.LN complex did not displace LN. These findings suggest the two ligands bind to proximal but distinct sites on m4-1BB. This is supported by the observation that six of eight anti-m4-1BB monoclonal antibodies blocked the interaction between 4-1BB and 4-1BBL, while seven blocked LN binding. Ligand and monoclonal antibody binding studies with a truncated protein lacking the amino-terminal LN-homologous domain of m4-1BB demonstrated that regions downstream of the LN-homologous domain participate in LN binding and that the intact protein is required for m4-1BBL binding. Studies with h4-1BB showed that h4-1BB only bound h4-1BBL, indicating that the ECM binding activity of 4-1BB is not conserved across species. This finding allowed the construction of murine/human 4-1BB chimeras, which permitted further dissection of the regions of 4-1BB involved in LN and 4-1BBL binding and suggests that sequence differences in the LN-homologous domain of h4-1BB in part account for the inability of h4-1BB to bind ECM proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045669     DOI: 10.1074/jbc.272.10.6448

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 2.  Cancer vaccines in old age.

Authors:  Claudia Gravekamp
Journal:  Exp Gerontol       Date:  2007-01-02       Impact factor: 4.032

3.  CD137 is required for M cell functional maturation but not lineage commitment.

Authors:  En Hui Hsieh; Xiomara Fernandez; Jing Wang; Mary Hamer; Stephanie Calvillo; Michael Croft; Byoung S Kwon; David D Lo
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

4.  CD137-induced apoptosis is independent of CD95.

Authors:  J Michel; S Pauly; J Langstein; P H Krammer; H Schwarz
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

5.  Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.

Authors:  Benyue Zhang; Charles H Maris; Juergen Foell; Jason Whitmire; Liguo Niu; Jing Song; Byoung S Kwon; Anthony T Vella; Rafi Ahmed; Joshy Jacob; Robert S Mittler
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

6.  Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.

Authors:  Aruna Bitra; Tzanko Doukov; Jing Wang; Gaelle Picarda; Chris A Benedict; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-12-14       Impact factor: 5.157

Review 7.  The importance of the age factor in cancer vaccination at older age.

Authors:  Claudia Gravekamp
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

8.  Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies.

Authors:  Shravan Madireddi; So-Young Eun; Seung-Woo Lee; Ivana Nemčovičová; Amit Kumar Mehta; Dirk M Zajonc; Nozomu Nishi; Toshiro Niki; Mitsuomi Hirashima; Michael Croft
Journal:  J Exp Med       Date:  2014-06-23       Impact factor: 14.307

Review 9.  4-1BB: A promising target for cancer immunotherapy.

Authors:  Alyssa Min Jung Kim; Macy Rose Nemeth; Seung-Oe Lim
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

10.  CD137 signaling enhances tight junction resistance in intestinal epithelial cells.

Authors:  Veronica Gusti; Kaila M Bennett; David D Lo
Journal:  Physiol Rep       Date:  2014-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.